Novel Treatments for Stomach Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing new combinations of drugs to treat advanced stomach cancer that can't be removed by surgery or has spread. Researchers want to see if these drug combinations are effective and safe, and how the body handles them. A group of patients will participate to find the best dose.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the XELOX treatment generally safe for humans?
What makes the drug AZD2936, FOLFOX, MEDI5752, XELOX unique for stomach cancer treatment?
This treatment is unique because it combines traditional chemotherapy (FOLFOX and XELOX) with MEDI5752, a novel bispecific antibody that targets two immune checkpoints, PD-1 and CTLA4, potentially enhancing the immune system's ability to fight cancer. This combination aims to improve outcomes by leveraging both chemotherapy and advanced immunotherapy.45678
What data supports the effectiveness of the drug AZD2936, FOLFOX, FOLFOX4, FOLFOX6, FOLFOX7, MEDI5752, Volrustomig, MEDI-5752, PD-1/CTLA-4 bispecific mAb, PD-l/CTLA-4 DuetMab, XELOX, Capecitabine/Oxaliplatin for stomach cancer?
Research shows that combinations like FOLFOX and XELOX, which include drugs like oxaliplatin and capecitabine, are effective in treating advanced gastric (stomach) cancer. Additionally, MEDI5752, which targets immune checkpoints, has shown promising results in various tumors, suggesting potential benefits for stomach cancer as well.457910
Are You a Good Fit for This Trial?
Adults over 18 with a body weight above 35 kg, diagnosed with advanced gastric or gastroesophageal junction adenocarcinoma that can't be surgically removed or has spread, and who haven't been treated for it yet. Participants should have a life expectancy of at least 12 weeks and good performance status (able to carry out daily activities). Those with active infections, previous immune-oncology treatments, certain HER2-positive cancers, uncontrolled brain metastases, serious illnesses, another cancer history or uncontrollable ascites are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive novel combination therapies, including Rilvegostomig, AZD0901, volrustomig, XELOX, FOLFOX, and AZD7789, depending on the substudy
Follow-up
Participants are monitored for safety and effectiveness after treatment, including progression-free survival and overall survival
What Are the Treatments Tested in This Trial?
Interventions
- AZD2936
- FOLFOX
- MEDI5752
- XELOX
Find a Clinic Near You
Who Is Running the Clinical Trial?
AstraZeneca
Lead Sponsor
Sir Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from รcole nationale vรฉtรฉrinaire d'Alfort, MBA from HEC Paris
Dr. Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology
Pascal Soriot
AstraZeneca
Chief Executive Officer since 2012
Veterinary Medicine from รcole nationale vรฉtรฉrinaire d'Alfort, MBA from HEC Paris
Cristian Massacesi
AstraZeneca
Chief Medical Officer since 2021
MD from Marche Polytechnic University, Medical Oncology training at Royal Marsden Hospital, Kaplan Comprehensive Cancer Center, and European Institute of Oncology